Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 476 - 500 of 15172 in total
Ritiometan is a nasal spray which is marketed by the name Nécyrane in France. It is indicated for use in viral rhinitis/ the common cold.
Approved
Matched Iupac: … 2-({bis[(carboxymethyl)sulfanyl]methyl}sulfanyl)acetic acid
Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective...
Approved
Investigational
Withdrawn
Matched Iupac: … [3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
Matched Description: … inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and
Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the...
Approved
Matched Description: … count, and neuropsychiatric effects [A19635]. ... for its high replicative rate and genetic diversity [A19594]. ... achieve a SVR between 93 and 99% after 12 weeks of treatment [A7535]. …
Matched Mixtures name: … Ledipasvir and Sofosbuvir ... Sofosbuvir and Velpatasvir …
Matched Categories: … sofosbuvir and ledipasvir ... sofosbuvir and velpatasvir ... sofosbuvir, velpatasvir and voxilaprevir ... Nucleic Acids, Nucleotides, and Nucleosides …
Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and...
Approved
Investigational
Matched Description: … reducing the signs and symptoms in patients 2 years old and older. ... It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a ... This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and
Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.
Approved
Withdrawn
Matched Description: … Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity. …
Matched Categories: … Cough and Cold Preparations …
Approved
Matched Iupac: … -carbonyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-N-[(C-hydroxycarbonimidoyl)methyl]hexanimidic acid
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Vasopressin and Analogues ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.
Approved
Matched Description: … by staphylococci and by vancomycin-resistant Enterococcus faecium. ... Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections ... Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.
Approved
Investigational
Matched Description: … Ramelteon has not been shown to produce dependence and has shown no potential for abuse. …
Matched Categories: … Hypnotics and Sedatives …
Estradiol Benzoate is a pro-drug ester of DB00783, a naturally occurring hormone that circulates endogenously within the human body. Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone. As a pro-drug of estradiol, estradiol benzoate therefore has the same downstream...
Approved
Investigational
Vet approved
Matched Description: … a chance to enter systemic circulation and exert its estrogenic effects [A12102]. ... Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex ... same downstream effects within the body through binding to the Estrogen Receptor (ER) including ERα and
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.
Approved
Matched Description: … Food and Drug Administration (FDA) on June 17, 2005. ... Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil …
Elbasvir is a direct-acting antiviral medication used as part of combination therapy to treat chronic hepatitis C, an infectious liver disease caused by infection with hepatitis C virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in...
Approved
Matched Description: … with or without [ribavirin] depending on the presence of resistance-associated amino acid substitutions ... [A19593] Substitutions at amino acid positions 28, 30, 31, or 93 are known to confer resistance to elbasvir ... for genotype 1 and 97% and 100% for genotype 4 after 12 weeks of treatment. …
Matched Categories: … elbasvir and grazoprevir …
Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as remifentanil, are designed to be metabolically fragile and thus susceptible to rapid...
Approved
Investigational
Matched Description: … thus susceptible to rapid biotransformation and elimination as inactive metabolites. ... Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation ... [A214852,A214857] Remimazolam was the first "soft" benzodiazepine analog to be developed[A214862] and
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Benzodiazepines and benzodiazepine derivatives …
Ombitasvir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common...
Approved
Investigational
Matched Description: … FDA- and Health Canada-approved product Technivie. ... categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and ... Ombitasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly [FDA …
Matched Categories: … Amino Acids, Peptides, and Proteins ... ombitasvir, paritaprevir and ritonavir ... dasabuvir, ombitasvir, paritaprevir and ritonavir …
Sodium tetradecyl sulfate is an anionic surface-active agent which is used for its wetting properties in the industry and is also used in medicine as a blood vessel irritant and sclerosing agent for hemorrhoids and varicose veins . Sodium tetradecyl sulfate has been widely used since the 1950s, and in...
Approved
Matched Iupac: … [(7-ethyl-2-methylundecan-4-yl)oxy]sulfonic acid
Matched Description: … is also used in medicine as a blood vessel irritant and sclerosing agent for hemorrhoids and varicose ... sulfate is an anionic surface-active agent which is used for its wetting properties in the industry and ... Sodium tetradecyl sulfate has been widely used since the 1950s, and in 1978 the first successful report …
Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with ritonavir - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability...
Approved
Matched Description: … "boosts" lopinavir exposure and improves antiviral activity. ... Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability and ... [L11163] Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination …
Matched Mixtures name: … Lopinavir and Ritonavir ... Lopinavir and ritonavir ... Lopinavir and ritonavir …
Matched Categories: … lopinavir and ritonavir ... Metabolic Side Effects of Drugs and Substances …
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation....
Approved
Investigational
Matched Description: … In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. ... agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and ... These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges , eyes , and inner ear . Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone...
Approved
Matched Iupac: … tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Matched Description: … meninges[A215582], eyes[A215647], and inner ear[A215627]. ... [A215582] It has a very long half-life compared to other cephalosporins and is high penetrable into the ... Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins …
Matched Products: … Ceftriaxone and Dextrose …
Aripiprazole lauroxil is a long-acting injectable atypical antipsychotic drug used in the treatment of schizophrenia in adult patients. It is a prodrug of aripiprazole, which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors . Affecting about 1% of the...
Approved
Investigational
Matched Description: … It is a prodrug of [aripiprazole], which acts as a partial agonist at the D2 and 5-HT1A receptors, and ... catanoia, and negative symptoms that include social withdrawal, anhedonia, and flattening of emotional ... patients are faced with social stigma and discriminations. …
Matched Categories: … Aripiprazole and prodrugs …
Tezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) potentiator class. It was developed by Vertex Pharmaceuticals and FDA approved in combination with ivacaftor to manage cystic fibrosis. This drug was approved by the FDA on February 12, 2018. Cystic Fibrosis is an autosomal recessive disorder caused...
Approved
Investigational
Matched Description: … consequently abnormal fluid and ion transport across cell membranes. ... [L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to ... Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and
Matched Categories: … ivacaftor and tezacaftor ... ivacaftor, tezacaftor and elexacaftor …
Approved
Experimental
Matched Iupac: … 2-(2-{2-[2-(benzoylsulfanyl)acetamido]acetamido}acetamido)acetic acid
Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized by the deficiency of alpha-galactosidase A.[A259352,L46342] Unlike other forms of recombinant alpha-galactosidase A, such as agalsidase alfa and agalsidase beta, pegunigalsidase alfa uses a...
Approved
Investigational
Matched Description: … allowing it to reach target organs with a lower dose and frequency of administration. ... [A259352,L46342] Unlike other forms of recombinant alpha-galactosidase A, such as [agalsidase alfa] and ... While agalsidase alfa and agalsidase beta enter lysosomes via the mannose-6-phosphate (M6P) receptor, …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated...
Approved
Matched Description: … [A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated ... [A176606] Certolizumab does not require glycosylation for active function and hence, its production ... The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in...
Approved
Matched Description: … It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies ... [A32299] Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 ... [L45894] Ibrutinib was approved by the EMA in October 2014 [L45884] and by Health Canada in November …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
The World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980. However, there have been longstanding concerns that smallpox may be used as a bioweapon.[A35133,L3614] Tecovirimat is an antiviral drug that was identified via a high-throughput screen in 2002. It is effective against all orthopoxviruses,...
Approved
Investigational
Matched Description: … to treat monkeypox and cowpox in adults and children. ... [L40154] Tecovirimat is available as both oral and intravenous formulations.[L41835] ... The World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, …
The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.
Approved
Investigational
Matched Description: … cord, and in animal fats and oils. ... The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal …
Displaying drugs 476 - 500 of 15172 in total